DurAVR™ THV

About Anteris Technologies

Anteris Technologies is an ASX-listed innovator focused on revolutionizing the treatment of aortic stenosis through its biomimetic DurAVR™ TAVR system. The company has achieved significant clinical milestones, demonstrating best-in-class hemodynamic performance with zero prosthesis-patient mismatch in small annuli patients and sustained positive one-year data. Its strategy centers on executing the landmark PARADIGM pivotal trial—the first all-comers, head-to-head TAVI trial—to secure regulatory approvals in the US and EU, positioning DurAVR™ as a potential new standard of care in the high-growth structural heart market.

Therapeutic Areas